CDMO ROIS has acquired a commercial injectable manufacturing and packaging facility in Phoenix, Arizona. The move adds U.S.-based sterile fill-finish capability while building on the company's European base.
The Phoenix site strengthens ROIS's ability to develop and manufacture injectable medicines at commercial scale, enhancing capacity, flexibility and speed as well as adding new capabilities for ADC's and Cytotoxic LYO fill-finish.
ROIS specializes in injectable drug development and manufacturing, with end-to-end capabilities including clinical production through to large-scale commercial supply. The company said it continues to invest in facilities, equipment and talent.
With an expanded global footprint, ROIS is reinforcing its commitment to innovation, quality, and growth — positioning itself as the partner of choice for injectable medicines.
